Kee-Soo Ha1, JungHwa Lee2, Kwang Chul Lee3. 1. Department of Pediatrics, Guro Hospital, Korea University Medical Center, 148 Gurodong-ro, Guro-gu, Seoul, 152-703, Republic of Korea. 2. Department of Pediatrics, Guro Hospital, Korea University Medical Center, 148 Gurodong-ro, Guro-gu, Seoul, 152-703, Republic of Korea. leejmd@chol.com. 3. Department of Pediatrics, Anam Hospital, Korea University Medical Center, Seoul, Republic of Korea.
Abstract
Risk factors predicting intravenous immunoglobulin (IVIG) resistance in patients with Kawasaki disease (KD) were assessed according to the duration of illness prior to treatment. Of 555 KD patients included between 2008 and 2014, 362 were IVIG responders (65.2%) and 193 were IVIG non-responders (34.8%). The risk of IVIG resistance was inversely correlated with the duration of illness prior to treatment. Neutrophil dominance (≥ 80%) was significantly higher in IVIG non-responders regardless of the duration of pre-IVIG illness. While there were no differences between IVIG responders and non-responders who were diagnosed at < 3 days, increasing platelet count and decreasing liver enzyme levels were seen over time in IVIG responders, but not in IVIG non-responders. Multivariable analysis showed that, in addition to neutrophil levels ≥ 80%, risk factors for IVIG resistance were age ≤ 12 months for patients who were diagnosed at ≤ 3 days, and platelet count ≤ 300 × 103/μL and aspartate aminotransferase level ≥ 100 IU/L for patients who were diagnosed at ≥ 6 days. Conclusion: Predictors of IVIG resistance in patients with KD differ according to the duration of pre-treatment illness. Risk assessment according to the duration of illness may improve the prediction of IVIG resistance.What is Known:• Several systems have been developed to predict IVIG resistance in patients with KD but the sensitivity and specificity of these tools are insufficient and ethnic variations have been reported.What is New:• Predictors of IVIG resistance differ depending on the duration of illness prior to treatment.• Risk assessment according to the duration of pre-treatment illness may improve the ability to predict IVIG resistance.
Risk factors predicting intravenous immunoglobulin (IVIG) resistance in patients with Kawasaki disease (KD) were assessed according to the duration of illness prior to treatment. Of 555 KDpatients included between 2008 and 2014, 362 were IVIG responders (65.2%) and 193 were IVIG non-responders (34.8%). The risk of IVIG resistance was inversely correlated with the duration of illness prior to treatment. Neutrophil dominance (≥ 80%) was significantly higher in IVIG non-responders regardless of the duration of pre-IVIG illness. While there were no differences between IVIG responders and non-responders who were diagnosed at < 3 days, increasing platelet count and decreasing liver enzyme levels were seen over time in IVIG responders, but not in IVIG non-responders. Multivariable analysis showed that, in addition to neutrophil levels ≥ 80%, risk factors for IVIG resistance were age ≤ 12 months for patients who were diagnosed at ≤ 3 days, and platelet count ≤ 300 × 103/μL and aspartate aminotransferase level ≥ 100 IU/L for patients who were diagnosed at ≥ 6 days. Conclusion: Predictors of IVIG resistance in patients with KD differ according to the duration of pre-treatment illness. Risk assessment according to the duration of illness may improve the prediction of IVIG resistance.What is Known:• Several systems have been developed to predict IVIG resistance in patients with KD but the sensitivity and specificity of these tools are insufficient and ethnic variations have been reported.What is New:• Predictors of IVIG resistance differ depending on the duration of illness prior to treatment.• Risk assessment according to the duration of pre-treatment illness may improve the ability to predict IVIG resistance.
Authors: J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders Journal: N Engl J Med Date: 1986-08-07 Impact factor: 91.245
Authors: Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert Journal: Pediatrics Date: 2004-12 Impact factor: 7.124
Authors: K Furusho; T Kamiya; H Nakano; N Kiyosawa; K Shinomiya; T Hayashidera; T Tamura; O Hirose; Y Manabe; T Yokoyama Journal: Lancet Date: 1984-11-10 Impact factor: 79.321